Clinical trials
Metastatic Soft Tissue Sarcoma clinical trials
Below are recruiting metastatic soft tissue sarcoma clinical trials, each written for real people, not researchers. We’re tracking 90 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Phoenix, ArizonaAges 18 years+ - NCT06263231RecruitingPhase 3
Study of INT230-6 injection for soft tissue sarcoma
This study tests an experimental drug, INT230-6, injected directly into tumors, compared to the usual treatments for soft tissue sarcoma. It aims to see if the injection is safe and works better for people whose cancer has not responded to earlier treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT03965234RecruitingPhase 1/Phase 2
Lung infusion for colorectal cancer that has spread to the lungs
This trial tests a procedure where chemotherapy is delivered directly into the lungs during surgery to remove or destroy lung tumors. It aims to reduce the chance of cancer returning after surgery for people with colorectal cancer that has spread to the lungs.
Buffalo, New YorkAges 18 years+ - NCT06367075RecruitingPhase 2
Cadonilimab plus adriamycin for advanced soft tissue sarcoma
This trial tests a combination of two drugs—cadonilimab (a type of immunotherapy) and adriamycin (chemotherapy)—for adults with advanced soft tissue sarcoma that hasn't been treated before. The goal is to see if this combination helps shrink tumors or slow their growth.
Wuhan, HubeiAges 18–75 - NCT07705334RecruitingPhase 1
Study of SHY-ONC6 for advanced solid tumors
This trial tests a new drug called SHY-ONC6 that targets and breaks down cancer cells. It's for people with advanced solid tumors that haven't responded to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT05620693Recruiting
Cell therapy study for NY-ESO-1–positive soft tissue cancer
This trial tests an engineered immune cell treatment (NY-ESO-1 TCR-T) for people with advanced soft tissue sarcoma that has returned or spread after standard treatment. It aims to treat cancer cells that show a specific marker (NY-ESO-1) in the tumor.
Shenzhen, GuangdongAges 18–70 - NCT05146440RecruitingPhase 1/Phase 2
Test drug PM14 alone and with radiation for soft-tissue sarcoma
This early-phase study tests PM14 (a new cancer treatment) to see if it can shrink tumors in soft-tissue sarcoma. Some people also receive radiation, aiming to improve tumor control while keeping side effects manageable.
Zaragoza, AragonAges 18–75 - NCT04751409RecruitingPhase 2
Less versus more follow-up after sarcoma surgery
This trial compares two schedules of post-treatment check-ups to see which one better supports patient quality of life. You’d fill out surveys for up to two years to measure how you feel over time.
Houston, TexasAges 18 years+ - NCT06062927Recruiting
Genes and scans predict response to immunotherapy and targeted therapy for advanced sarcoma
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
Beijing, Beijing MunicipalityAges 18–75 - NCT05876715RecruitingPhase 1/Phase 2
Testing 3 immunotherapy drugs for hard-to-remove soft tissue cancer
This Phase 1/2 study tests lurbinectedin plus two immune checkpoint medicines (ipilimumab and nivolumab) for soft tissue sarcoma that is hard to remove or has spread. It aims to see how well the combination works and how safe it is, especially for people with limited treatment options.
Santa Monica, CaliforniaAges 18–90 - NCT06239272RecruitingPhase 1/Phase 2
Personalized treatment for NRSTS in children and young adults
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
Atlanta, GeorgiaAges Up to 30 years - NCT07507773RecruitingPhase 2
Radiation before surgery for limb or trunk wall sarcoma
This trial tests a shorter course of radiation given before surgery for soft tissue sarcoma in the arms, legs, or trunk wall. It aims to see if this approach works well long-term and may help you keep your limb.
LilleAges 18 years+ - NCT05333458RecruitingPhase 2
Atezolizumab plus selinexor for advanced alveolar soft tissue sarcoma
This Phase 2 trial tests whether combining atezolizumab with selinexor can slow or shrink advanced alveolar soft part sarcoma (ASPS) in people age 12 and older. It may help by improving the immune system’s ability to fight the cancer and stopping cancer cell growth signals.
Los Angeles, CaliforniaAges 12 years+ - NCT03016819RecruitingPhase 3
Test drugs anlotinib and catequentinib for advanced sarcoma
This Phase 3 study tests two anti-cancer medicines (anlotinib and catequentinib) for people with certain advanced soft-tissue sarcomas, including alveolar soft part sarcoma, synovial sarcoma, and leiomyosarcoma. It is designed for tumors that cannot be removed and that have either grown despite treatment or no longer respond to standard options.
Phoenix, ArizonaAges 18 years+ - NCT03805022RecruitingPhase 3
Extra chemotherapy around surgery for high-risk soft-tissue sarcoma
This trial tests whether giving stronger chemotherapy before and/or after surgery helps people with high-risk, resectable soft-tissue sarcoma. It aims to lower the chance the cancer comes back by improving treatment around the time of the operation.
BordeauxAges 18 years+ - NCT03967834Recruiting
Study of immune features in rare soft tissue sarcoma
This study looks at immune system “fingerprints” using tumor tissue from people with rare soft tissue sarcoma. It may help researchers understand what drives these cancers and guide future treatments.
BesançonAges 18 years+ - NCT04040205RecruitingPhase 2
Abemaciclib for sarcoma with specific cell-growth gene changes
This trial tests abemaciclib (a cancer medicine) in adults with advanced, unresectable bone or soft-tissue sarcoma that has certain gene changes in the “CDK pathway.” It aims to shrink tumors or slow growth in people whose tumors match the study’s biomarker and lab requirements.
Jacksonville, FloridaAges 18 years+ - NCT04307277RecruitingPhase 3
Checking chemotherapy before and after surgery for high-risk sarcoma
This Phase 3 trial tests whether giving chemotherapy around the time of surgery (before/after) can improve outcomes for people with high-risk localized soft-tissue sarcoma. It uses special tumor testing (CINSARC) to help identify higher-risk patients who may benefit.
BesançonAges 18 years+ - NCT04535271RecruitingPhase 2
Trabectedin, gemcitabine, and dacarbazine for advanced leiomyosarcoma
This Phase 2 study tests a combination of three anti-cancer medicines to shrink or control leiomyosarcoma that cannot be fully removed by surgery or has spread. It may help people whose cancer has grown after prior treatment.
Santa Monica, CaliforniaAges 18 years+ - NCT04577014RecruitingPhase 1/Phase 2
Retifanlimab plus chemotherapy for advanced soft tissue sarcoma
This trial tests retifanlimab (an immunotherapy that helps your immune system recognize cancer) combined with gemcitabine and docetaxel chemotherapy. It’s for people with advanced soft tissue sarcoma that can’t be safely removed with surgery, aiming to shrink tumors and improve outcomes.
New York, New YorkAges 18 years+ - NCT04757337RecruitingPhase 3
Oral chemotherapy comparison for older advanced soft-tissue cancer
This trial compares two chemotherapy medicines—oral cyclophosphamide versus doxorubicin—in people age 65 and older with advanced soft-tissue sarcoma that can’t be cured with surgery or radiation. It aims to see which treatment works better and is more tolerable for this age group.
ToulouseAges 65 years+ - NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Palo Alto, CaliforniaAges 1–30 - NCT06796543Recruiting
Radiation for young patients with sarcoma that has spread
This trial tests whether targeted radiation can help children and young adults with sarcoma that has spread to a few spots in the body. It's for those who are newly diagnosed (Stratum A) or whose sarcoma has come back or worsened (Stratum B).
Washington D.C., District of ColumbiaAges Up to 39 years - NCT04995003RecruitingPhase 1
HER2 CAR T plus pembrolizumab for advanced HER2 sarcoma
This Phase 1 study tests a personalized immune-cell treatment (HER2 CAR T cells) given with an immune “checkpoint” medicine (pembrolizumab or another checkpoint blocker) to shrink advanced HER2-positive sarcoma. It may help patients whose cancer is progressing or coming back after prior treatment.
Houston, TexasAges 1–25
Hear when a new Metastatic Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Metastatic Soft Tissue Sarcoma trials by city
Studies with a site in or near these metro areas.
Metastatic Soft Tissue Sarcoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for metastatic soft tissue sarcoma?
- Yes. Clin2 currently lists 90 recruiting metastatic soft tissue sarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic soft tissue sarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic soft tissue sarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.